Mounjaro International Purchase Legalities: What U.S. Patients Need to Know in 2026

Is It Legal to Buy Mounjaro from a Foreign Pharmacy?

For U.S. Residents, buying Mounjaro from a Canadian, Mexican, or other foreign pharmacy and bringing it or mailing it into the United States is almost always illegal. Federal law, specifically 21 U.S.C. § 331, prohibits the importation of unapproved or non-FDA-regulated drugs. Tirzepatide manufactured outside an FDA-inspected supply chain falls into that category regardless of where it is purchased. The FDA's personal importation policy states that "it is generally illegal for individuals to import drugs into the U.S. For personal use." The agency does exercise enforcement discretion in narrow situations, but tirzepatide does not meet those criteria as of 2026.

What the FDA's Personal Importation Policy Actually Says

The FDA published guidance allowing limited enforcement discretion for personal drug importation when all of the following conditions are met: the drug is for a serious condition for which no U.S. Treatment is available, there is no evidence of commercialization, the drug poses no unreasonable risk, and the quantity does not exceed a 90-day supply. Tirzepatide fails condition one immediately. FDA-approved tirzepatide products (Mounjaro and Zepbound) are commercially available in the United States. The FDA's importation guidance page makes this explicit.

Country-by-Country Realities

Canada. Health Canada regulates tirzepatide as a prescription drug. Canadian pharmacies that ship to U.S. Addresses violate both Canadian pharmacy law and the U.S. Federal Food, Drug, and Cosmetic Act simultaneously. Several online "Canadian" pharmacies are actually drop-shippers sourcing product from unverified manufacturers. The FDA's BeSafeRx campaign documents over 95% of online pharmacies operating outside applicable laws.

Mexico. Tirzepatide is available by prescription in Mexico. Carrying a personal supply across the border falls under U.S. Customs and Border Protection discretion, but CBP's policy mirrors the FDA's: drugs must be FDA-approved and in original manufacturer packaging with a valid prescription. A traveler stopped at the border with foreign-packaged tirzepatide may have it confiscated and face potential civil penalty.

United Kingdom and EU. The Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA) both approved tirzepatide in 2023, but their authorizations do not confer any legal right to import into the U.S. Mailing prescription drugs from the UK or EU to a U.S. Address violates the FDCA and the exporting country's own pharmaceutical export regulations.

Counterfeit Risk Is Real

The FDA has issued multiple warnings about counterfeit and mislabeled GLP-1 medications circulating through unauthorized online channels. Counterfeits may contain incorrect doses, microbial contamination, or entirely different active ingredients. A 2024 FDA laboratory analysis found some products sold as semaglutide contained no active GLP-1 compound at all.

The Clinical Case for Tirzepatide: Why Patients Are Seeking It Abroad

Patients are looking internationally because tirzepatide's efficacy is dramatic and its U.S. Cost, without insurance, is prohibitive.

SURMOUNT Trial Data

In SURMOUNT-1 (N=2,539), adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related complication who received tirzepatide 15 mg lost a mean of 20.9% of body weight at 72 weeks, compared with 3.1% in the placebo group (P<0.001). That magnitude of weight loss matches outcomes previously seen only with bariatric surgery.

In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced HbA1c by a mean of 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg, with 40% of tirzepatide patients achieving an HbA1c below 5.7% (P<0.001 for both outcomes). The glycemic data reinforce why patients with type 2 diabetes seek continuous access.

FDA-Approved Indications

The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023. The FDA approval announcement for Zepbound specifies indicated use in adults with BMI 30 or above, or BMI 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea.

Legal Ways to Reduce Mounjaro Costs in the United States

The list price of Mounjaro runs approximately $1,069 per month for a four-pen box. Multiple legitimate pathways reduce that cost substantially.

Lilly's Savings Card Program

Eli Lilly offers a savings card that reduces out-of-pocket cost to as low as $25 per month for commercially insured patients, and to $550 per month for uninsured patients who qualify. Eligibility requires a valid U.S. Prescription and commercial (non-government) insurance or documented uninsured status. The program is managed through LillyInsulin.com and the Mounjaro savings page. Income limits and program caps apply; as of 2026, the uninsured savings offer requires annual household income below 400% of the federal poverty level.

Lilly Cares Foundation Patient Assistance

For patients whose income falls below specific thresholds and who have no insurance coverage, the Lilly Cares Foundation may provide tirzepatide at no cost. Applications are submitted through LillyCares.com. A prescribing physician must complete and sign the application. Processing time is typically 10 to 14 business days.

Compounded Tirzepatide: Legal Status as of 2026

Compounded tirzepatide from FDA-registered 503A and 503B pharmacies remains a legal option under current FDA enforcement policy, though that policy is actively evolving.

The FDA declared tirzepatide shortage-resolved in late 2024 and issued a compliance policy giving compounders a wind-down period. As of early 2026, the FDA has extended some enforcement discretion timelines, but 503A pharmacies compounding commercially available strengths face increasing scrutiny. The FDA's compounding guidance page for tirzepatide should be checked for current status before prescribing or dispensing.

Compounded tirzepatide can cost 60% to 80% less than brand Mounjaro per dose. Patients accessing this route should verify their pharmacy's 503A or 503B registration through the FDA's registered outsourcing facility list.

Manufacturer Coupons vs. GoodRx vs. Mark Cuban's Cost Plus Drugs

GoodRx shows Mounjaro discounts in some pharmacy networks, but effective pricing varies by zip code and pharmacy. Cost Plus Drugs (Mark Cuban's pharmacy) does not currently carry brand tirzepatide. Generic tirzepatide does not exist as of 2026; Lilly's exclusivity runs through at least 2036 for the base compound. GoodRx discounts typically bring the price to $850 to $950 for a four-pen box, well below list but still above Lilly's savings-card floor for insured patients.

HSA and FSA Eligibility for Mounjaro

Tirzepatide qualifies as an eligible medical expense under IRS Publication 502 (Medical and Dental Expenses), which covers prescription medications obtained lawfully with a valid prescription. Patients may pay for Mounjaro or Zepbound directly from a Health Savings Account (HSA) or Flexible Spending Account (FSA) without tax penalty.

How HSA Payment Works

HSA funds are contributed pre-tax, grow tax-free, and can be withdrawn tax-free for qualifying medical expenses. Paying a $1,069 monthly Mounjaro bill from an HSA effectively reduces the real cost by your marginal tax rate. For a patient in the 22% federal bracket, the effective out-of-pocket cost falls to approximately $834 per month before any savings-card stacking.

HSA and savings-card stacking is permitted in most cases, but patients should verify with their HSA administrator. Some plans prohibit double-dipping when a manufacturer's coupon reduces cost below the patient's actual deductible obligation.

FSA Considerations

FSA funds expire at year-end under most plans (with a $660 rollover cap in 2026). Patients planning a full year of tirzepatide therapy should load their FSA to the maximum ($3,300 individual / $6,600 family in 2026) and use those funds before the December 31 deadline. Tirzepatide prescribed for weight management rather than type 2 diabetes still qualifies as a medical expense when prescribed by a licensed provider, since IRS Publication 502 does not restrict eligibility by diagnosis category.

Documentation Requirements

Keep the prescription label, pharmacy receipt, and the prescriber's clinical note on file. The IRS requires that HSA and FSA reimbursements be for a "medical purpose prescribed by a physician," which tirzepatide clearly satisfies given its FDA-approved indications.

What Telehealth Platforms Can and Cannot Do

A licensed U.S. Telehealth platform can prescribe tirzepatide legally if the prescribing clinician holds a valid state license where the patient is located, the prescriber conducts an appropriate evaluation (including review of BMI, comorbidities, and contraindications), and the prescription is filled at an FDA-licensed U.S. Pharmacy or a verified 503A/503B compounding pharmacy.

A telehealth platform cannot legally source tirzepatide from outside the United States, cannot help a patient "import" product from a foreign seller, and cannot guarantee that a compounding pharmacy's product is bioequivalent to the brand reference listed drug. The FDA's guidance on telehealth prescribing notes that the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 applies to all controlled substances; tirzepatide is not a controlled substance but similar principles of prescriber-patient relationship and in-state licensure apply.

Spotting Illegal Online Pharmacies Selling Tirzepatide

The FDA's BeSafeRx program identifies these red flags for illegal online pharmacies:

• No requirement for a valid prescription
• Physical address outside the United States or no address listed
• Prices dramatically below U.S. Market (more than 80% below list price)
• No licensed pharmacist available to answer questions
• Offering to "prescribe" after a short online questionnaire with no licensed U.S. Provider review

Patients who suspect an illegal pharmacy can report it to the FDA's MedWatch program or the National Association of Boards of Pharmacy (NABP) Not Recommended list. The NABP has flagged over 35,000 websites as operating outside safe pharmacy practices.

What Happens if You Are Caught Importing Tirzepatide

Personal importation enforcement ranges from confiscation without penalty at the border to civil fines and, in rare cases involving large quantities or commercial intent, criminal prosecution. The FDA generally exercises discretion for quantities up to a 90-day supply of drugs meeting the personal-use criteria listed above, but tirzepatide does not meet those criteria. CBP officers have authority to seize foreign-origin pharmaceutical products at ports of entry. Seized product is destroyed; no refund is issued.

Beyond the legal risk, patients face the medical risk of receiving an adulterated or counterfeit product. Insulin pens and auto-injector devices, which tirzepatide uses, require specific cold-chain handling at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). International mail orders routinely break the cold chain. A degraded tirzepatide product may have reduced potency, causing subtherapeutic glucose control in a patient with type 2 diabetes, a medically serious outcome.

Clinical Bottom Line on Cost Access

The most cost-effective legal pathway in 2026 depends on insurance status:

Commercially insured patients: Apply the Lilly savings card first. Most commercially insured patients pay $25 per month. If the savings card is denied, appeal through the insurer's formulary exception process using SURMOUNT or SURPASS trial data as clinical evidence of medical necessity.

Uninsured patients: Combine the Lilly uninsured savings offer ($550/month cap) with HSA pre-tax contributions where available. If income qualifies, apply to Lilly Cares for free drug. Compounded tirzepatide from a verified 503A pharmacy may be appropriate while compound availability persists.

Medicare/Medicaid patients: Lilly's commercial savings card does not apply to government insurance. The Inflation Reduction Act's $2,000 out-of-pocket cap for Medicare Part D enrollees takes effect in 2025 and limits annual drug costs, but monthly tirzepatide cost may still reach that cap by spring. Ask your prescriber about a prior authorization appeal using the ADA Standards of Care in Diabetes 2024, which recommends GLP-1/GIP agonists as a preferred second-line agent in type 2 diabetes with cardiovascular risk factors.

The single most effective step an uninsured patient can take before considering any foreign purchase is to contact Lilly directly at 1-800-545-5979 to confirm current program eligibility. Program terms update quarterly, and the savings field as of mid-2026 may differ from what was published in early 2025.